Compare Cytokinetics Inc (CYTK) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Harmony Gold Mining Co. — how do they compare? Cytokinetics Inc trades at $62.72 (market cap $8.62B), while Harmony Gold Mining Co. trades at $16.91 (market cap $10.02B). The key difference: Harmony Gold Mining Co. is the larger of the two by market cap, and Harmony Gold Mining Co. pays a 4.63% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Harmony Gold Mining Co. for 45 Days on average.
| CYTK | HMY | |
|---|---|---|
Market Cap | $8.62B | $10.02B |
Volume | 2,594,626 | 3,643,683 |
Sector | Health | Basic Materials |
52-Week High | $87.26 | $26.04 |
52-Week Low | $54.76 | $13.32 |
Typical Hold Time | 19 Days | 45 Days |
Enterprise Value | $8.72B | $10.07B |
Dividend Yield | — | 4.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
HMY trades at $16.83, up 2.03% today, amid a bearish technical signal from moving averages. The company reported record fiscal 2026 revenue of $99.2B and net income of $29.3B, with a strong net margin of 29.57%. Recent news highlights its strategic shift toward copper production, with the CEO noting the real payoff is expected after 2030. Cash flow from operations surged to $22.65B in 2025, though 2026 projections show a net cash outflow due to heavy investing.
The outlook is mixed: strong fundamentals and undervalued ratios (P/E of 6.02) support upside, but technical weakness and two recent EPS misses pose near-term risks. Analyst consensus is cautious with 70% hold ratings. Key opportunities include copper diversification; risks involve execution on investments and gold price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
